San Diego, CA – According to filings with the U.S. Securities and Exchange Commission, Evofem Biosciences is raising $25,000,000.00 in new funding. Sources indicate as part of senior management Chief Financial Officer, Justin File played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Evofem Biosciences

Evofem Biosciences, Inc., is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women’s sexual and reproductive health. Evofem Biosciences aims to advance the lives of women by developing innovative solutions, such as woman-controlled contraception and potential protection from certain sexually transmitted infections. The Company’s lead product candidate, Phexxi, is currently being reviewed by the U.S. Food and Drug Administration for prevention of pregnancy.

To learn more about Evofem Biosciences, visit http://www.evofem.com/

Contact:
Justin File, Chief Financial Officer
858-550-1900
jfile@evofem.com
https://www.linkedin.com/in/justin-file/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved